Reference: FOI.ICB-2526/157

Subject: Bevacizumab Gamma (Lytenava®) for Neovascular (wet) Age-related Macular Degeneration (NICE TA1022)

I can confirm that the ICB does hold the information requested; please see responses below:

QUESTION	RESPONSE
Under the Freedom of Information Act 2000, please provide the following recorded information held by your Integrated Care Board regarding use of bevacizumab gamma (Lytenava®) for neovascular (wet) age-related macular degeneration (NICE TA1022): **Scope & period** 1. 1 June 2025 – 30 June 2025 2. 1 July 2025 – 31 July 2025 **Format & identifiers** • Please provide the data in CSV or XLSX. • Drug identifiers for clarity: bevacizumab gamma (brand: Lytenava®; NICE TA1022; if useful for your systems, PIP code often referenced is *1215680*). **Notes** • I am requesting aggregate figures only; no patient-level data are required. • If your ICB does not hold some or all of this information but your provider Trusts do, please advise and/or transfer this request to the relevant bodies under the FOI Section 45 Code of Practice. • If any figure is ≤5 and you consider disclosure risky to anonymity, please use standard rounding/redaction (e.g., "≤5").	

Request	
• Total number of Blueteq prior-approval forms submitted for bevacizumab gamma (Lytenava) for wet AMD within your ICB. Please split totals into: a) Initiation forms (treatment starts) b) Continuation forms (ongoing approvals / renewals) If held, please also provide a breakdown by provider Trust within your ICB.	• Zero forms submitted

The information provided in this response is accurate as of 22 August 2025 and has been approved for release by Dr Joanne Medhurst, Chief Medical Officer for NHS Bristol, North Somerset and South Gloucestershire ICB.